• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Addex Pharmaceuticals - Product Pipeline Review - Q4 2010 - Product Image

Addex Pharmaceuticals - Product Pipeline Review - Q4 2010

  • ID: 1448669
  • December 2010
  • 65 pages
  • Global Markets Direct

Addex Pharmaceuticals – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Addex Pharmaceuticals - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Addex Pharmaceuticals - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Addex Pharmaceuticals human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Addex Pharmaceuticals Snapshot
Addex Pharmaceuticals Overview
Key Information
Key Facts
Addex Pharmaceuticals – Research and Development Overview
Key Therapeutic Areas
Addex Pharmaceuticals – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Addex Pharmaceuticals – Pipeline Products Glance
Addex Pharmaceuticals Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Addex Pharmaceuticals–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Addex Pharmaceuticals – Drug Profiles
ADX48621
Product Description
Mechanism of Action
R&D Progress
ADX68692
Product Description
Mechanism of Action
R&D Progress
ADX68693
Product Description
Mechanism of Action
R&D Progress
ADX71943
Product Description
Mechanism of Action
R&D Progress
GLP-1R PAM
Product Description
Mechanism of Action
R&D Progress
mGluR2 NAM
Product Description
Mechanism of Action
R&D Progress
A2A PAM
Product Description
Mechanism of Action
R&D Progress
GIPR PAM
Product Description
Mechanism of Action
R&D Progress
IL1R1 NAM
Product Description
Mechanism of Action
R&D Progress
mGluR4 PAM Program
Product Description
Mechanism of Action
R&D Progress
mGluR7 NAM Program
Product Description
Mechanism of Action
R&D Progress
Orexin-2R NAM
Product Description
Mechanism of Action
R&D Progress
TNFR1 NAM
Product Description
Mechanism of Action
R&D Progress
Addex Pharmaceuticals – Pipeline Analysis
Addex Pharmaceuticals – Pipeline Products by Therapeutic Class
Addex Pharmaceuticals Pipeline Products By Target
Addex Pharmaceuticals – Pipeline Products by Route of Administration
Addex Pharmaceuticals – Pipeline Products by Molecule Type
Addex Pharmaceuticals – Recent Pipeline Updates
Addex Pharmaceuticals - Dormant Projects
Addex Pharmaceuticals - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Adenosine A3 Antagonist
ADX10059
ADX10061
Addex Pharmaceuticals – Company Statement
Addex Pharmaceuticals – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Sep 08, 2010: Addex Awarded Michael J. Fox Foundation Grant For ADX48621 To Treat Levodopa-Induced Dyskinesia In Parkinson’s
Sep 02, 2010: Addex's mGluR2 Shows Efficacy In Alzheimer’s Disease Model
Jul 13, 2010: Addex's ADX71943 Demonstrates Efficacy In Osteoarthritis Pain Model
Jun 15, 2010: Addex’s ADX48621 Effective In Preclinical Parkinson’s Disease Studies
Feb 08, 2010: Addex Demonstrates Analgesic Effects Of ADX71943 In Three Preclinical Models
Dec 15, 2009: Addex Pharmaceuticals Terminates The Development Of ADX10059 For The Treatment Of Gastroesophageal Reflux Disease And Migraine Prophylaxis
Dec 15, 2009: Addex Pharmaceuticals Terminates The Development Of ADX10059 For The Treatment Of Gastroesophageal Reflux Disease And Migraine Prophylaxis
Nov 23, 2009: Addex Pharmaceuticals Announces Positive Primate Parkinson’s Data Of ADX48621
Nov 16, 2009: Addex ADX10059 Monotherapy Is Effective On GERD Symptoms In Phase IIb Clinical Trial
Nov 03, 2009: Addex Presents ADX10059 PD-LID Data At GPCR Drug Discovery Conference
Financial Deals Landscape
Addex Pharmaceuticals, Deals Volume Summary, 2004 to YTD 2010
Addex Pharmaceuticals, Deals Summary By Region, 2004 to YTD 2010
Addex Pharmaceuticals, Deals Summary, 2004 to YTD 2010
Addex Pharmaceuticals Detailed Deal Summary
Venture Financing
Addex Pharmaceuticals Secures $32 Million In Series C Financing
Addex Pharmaceuticals Secures $39 Million In Series B Financing
Equity Offering
Addex Pharmaceuticals Completes Initial Public Offering Of $111.3 Million
Asset Finance
Ghodawat Industries And Topaz Investments Completes Project Financing Of $5 Million For Wind Power Project In Maharashtra, India
Licensing Agreements
Addex Pharmaceuticals Extends Collaboration Agreement With Merck & Co.
Addex Pharmaceuticals Enters Into A License Agreement With Merck & Co
Addex Pharmaceuticals Enters Into Collaboration And Licensing Agreement With Merck & Co
Addex Pharmaceuticals Enters Into Licensing Agreement With Ortho-McNeil
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS